Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Verici Dx Plc ( (GB:VRCI) ).
Verici Dx plc has reported a significant increase in its Tutivia™ testing order rate, with a 68% rise in Q1 2025 compared to the previous quarter. This growth comes ahead of a pending decision from Medicare contractor MolDX regarding coverage, which is expected to further boost adoption. The company achieved a milestone payment under its commercial contract with Thermo Fisher and is actively managing costs to extend its cash runway. Despite challenges in insurance coverage and market uncertainties, Verici Dx remains focused on expanding its presence in the transplant diagnostics field and anticipates further growth as insurance coverage is established.
More about Verici Dx Plc
Verici Dx plc is a developer of advanced clinical diagnostics focused on organ transplant. The company offers a suite of leading-edge tests, including Tutivia™ and PTRA, which form a kidney transplant platform aimed at personalized patient and organ response risk management. Their technology leverages artificial intelligence-assisted transcriptomic analysis to provide RNA signatures crucial for transplant prognosis, addressing risks such as injury, rejection, and graft failure.
YTD Price Performance: -16.13%
Average Trading Volume: 1,121,525
Technical Sentiment Signal: Strong Buy
Current Market Cap: £7.88M
Learn more about VRCI stock on TipRanks’ Stock Analysis page.